Prognostic value of Ki67 and p53 in patients with estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer: Validation of the cut-off value of the Ki67 labeling index as a predictive factor

Ohara,Masahiro; Matsuura,Kazuo; Akimoto,Etsushi; Noma,Midori; Doi,Mihoko; Nishizaka,Takashi; Kagawa,Naoki; Itamoto,Toshiyuki

doi:10.3892/mco.2016.776

Prognostic value of Ki67 and p53 in patients with estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer: Validation of the cut-off value of the Ki67 labeling index as a predictive factor

Authors:
- Masahiro Ohara
- Kazuo Matsuura
- Etsushi Akimoto
- Midori Noma
- Mihoko Doi
- Takashi Nishizaka
- Naoki Kagawa
- Toshiyuki Itamoto
View Affiliations

Affiliations: Department of Breast Surgery, Hiroshima Prefectural Hospital, Hiroshima 734‑8530, Japan, Department of Clinical Oncology, Hiroshima Prefectural Hospital, Hiroshima 734‑8530, Japan, Department of Clinical Laboratory, Hiroshima Prefectural Hospital, Hiroshima 734‑8530, Japan, Kagawa Breast Clinic, Hiroshima 730‑0029, Japan
Published online on: February 10, 2016 https://doi.org/10.3892/mco.2016.776
Pages: 648-654

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to evaluate the significance of the Ki67 labeling index and p53 status as prognostic and predictive indicators of operable estrogen receptor (ER)‑positive and human epidermal growth factor receptor 2 (HER2)‑negative breast cancer. Among 697 consecutive patients with primary breast cancer who underwent curative surgery between 2002 and 2013, 308 patients with ER‑positive and HER2‑negative breast cancer were assessed. The results of the multivariate Cox analysis demonstrated that a high Ki67 labeling index was significantly associated with a short recurrence‑free interval (RFI) (p=0.004) and was marginally associated with a worse overall survival (p=0.074). A positive p53 status was not associated with worse outcomes. To validate the cut‑off values of the Ki67 labeling index for identifying patients who may benefit from additional chemotherapy, prognostic factors were investigated in breast cancer patients treated postoperatively with endocrine therapy alone. Analysis of receiver operating characteristic curves demonstrated that a Ki67 labeling index cut‑off of 20.0% was optimal for predicting recurrence among patients who did not receive adjuvant chemotherapy. The 5‑year RFIs for patients with Ki67 <20 and ≥20% were 97.2 and 86.6%, respectively (p=0.0244). A high Ki67 labeling index (≥20%) was significantly associated with large tumors (p<0.01), lymph node metastasis (p=0.0236) and positive p53 status (p<0.001). The univariate analysis demonstrated that Ki67 labeling index ≥20%, lymph node metastasis and progesterone receptor negativity were significant worse prognostic factors for RFI (p=0.0333, 0.0116 and 0.0573, respectively). The Ki67 labeling index was found to be a useful prognostic factor in patients with ER‑positive and HER2‑negative breast cancer and the cut‑off values of the Ki67 labeling index for making a decision regarding adjuvant treatment were validated.

View Figures

View References

1	Badve S and Nakshatri H: Oestrogen-receptor-positive breast cancer: Towards bridging histopathological and molecular classifications. J Clin Pathol. 62:6–12. 2009. View Article : Google Scholar : PubMed/NCBI
2	Hortobagyi GN: Treatment of breast cancer. N Engl J Med. 339:974–984. 1998. View Article : Google Scholar : PubMed/NCBI
3	Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 351:1451–1467. 1998. View Article : Google Scholar : PubMed/NCBI
4	Mauri D, Pavlidis N, Polyzos NP and Ioannidis JP: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: Meta-analysis. J Natl Cancer Inst. 98:1285–1291. 2006. View Article : Google Scholar : PubMed/NCBI
5	Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar : PubMed/NCBI
6	Azim HA Jr, Michiels S, Zagouri F, Delaloge S, Filipits M, Namer M, Neven P, Symmans WF, Thompson A, André F, et al: Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. Ann Oncol. 24:647–654. 2013. View Article : Google Scholar : PubMed/NCBI
7	Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ, Albain KS, Andre F, Bergh J, et al: Panel members: Personalizing the treatment of women with early breast cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 24:2206–2223. 2013. View Article : Google Scholar : PubMed/NCBI
8	Domagala W, Markiewski M, Harezga B, Dukowicz A and Osborn M: Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: Its relationship with vimentin and p53 protein. Clin Cancer Res. 2:147–154. 1996.PubMed/NCBI
9	Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, Coates AS, Collins J, Castiglione-Gertsch M and Gusterson BA: International Breast Cancer Study Group: Ki-67 expression in breast carcinoma: Its association with grading systems, clinical parameters, and other prognostic factors - a surrogate marker? Cancer. 97:1321–1331. 2003. View Article : Google Scholar : PubMed/NCBI
10	de Azambuja E, Cardoso F, de Castro G Jr, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ and Paesmans M: Ki-67 as prognostic marker in early breast cancer: A meta-analysis of published studies involving 12,155 patients. Br J Cancer. 96:1504–1513. 2007. View Article : Google Scholar : PubMed/NCBI
11	Gnant M, Harbeck N and Thomssen C: St. Gallen 2011: Summary of the Consensus Discussion. Breast Care (Basel). 6:136–141. 2011. View Article : Google Scholar : PubMed/NCBI
12	Untch M, Gerber B, Möbus V, Schneeweiss A, Thomssen C, von Minckwitz G, Beckmann MW, Blohmer JU, Costa SD, Diedrich K, et al: Zurich Consensus: Statement of German Experts on St. Gallen Conference 2011 on Primary Breast Cancer (Zurich 2011). Breast Care (Basel). 6:144–152. 2011. View Article : Google Scholar
13	Untch M, Gerber B, Harbeck N, Jackisch C, Marschner N, Möbus V, von Minckwitz G, Loibl S, Beckmann MW, Blohmer JU, et al: 13th St. Gallen international breast cancer conference 2013: Primary therapy of early breast cancer evidence, controversies, consensus - opinion of a German team of experts (Zurich 2013). Breast Care (Basel). 8:221–229. 2013.PubMed/NCBI
14	Millar EK, Graham PH, McNeil CM, Browne L, O'Toole SA, Boulghourjian A, Kearsley JH, Papadatos G, Delaney G, Fox C, et al: Prediction of outcome of early ER⁺ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. Br J Cancer. 105:272–280. 2011. View Article : Google Scholar : PubMed/NCBI
15	Kobayashi T, Iwaya K, Moriya T, Yamasaki T, Tsuda H, Yamamoto J and Matsubara O: A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer. BMC Clin Pathol. 13:52013. View Article : Google Scholar : PubMed/NCBI
16	Boyle DP, McArt DG, Irwin G, Wilhelm-Benartzi CS, Lioe TF, Sebastian E, McQuaid S, Hamilton PW, James JA, Mullan PB, et al: The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer. Histopathology. 65:340–352. 2014. View Article : Google Scholar : PubMed/NCBI
17	Yamamoto M, Hosoda M, Nakano K, Jia S, Hatanaka KC, Takakuwa E, Hatanaka Y, Matsuno Y and Yamashita H: p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors. Cancer Sci. 105:81–88. 2014. View Article : Google Scholar : PubMed/NCBI
18	Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
19	Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B and Senn HJ: Panel members: Meeting highlights: International Expert Consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 16:1569–1583. 2005. View Article : Google Scholar : PubMed/NCBI
20	Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B and Senn HJ: 10th St. Gallen conference: Progress and promise: Highlights of the International Expert Consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 18:1133–1144. 2007. View Article : Google Scholar : PubMed/NCBI
21	Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B and Senn HJ: Panel members: Thresholds for therapies: Highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 20:1319–1329. 2009. View Article : Google Scholar : PubMed/NCBI
22	Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B and Senn HJ: Panel members: Strategies for subtypes - dealing with the diversity of breast cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 22:1736–1747. 2011. View Article : Google Scholar : PubMed/NCBI
23	National Comprehensive Cancer Network: Breast Cancer. http://ww.nccn.org/professionals/physician_gls/f_guidelines.asp
24	The Japanese Breast Cancer Society: General Rules for Clinical and Pathological Recording of Breast Cancer (16th). Kanehara Shuppan, Tokyo: 2008.
25	Allred DC, Harvey JM, Berardo M and Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 11:155–168. 1998.PubMed/NCBI
26	Iwaya K, Tsuda H, Hiraide H, Tamaki K, Tamakuma S, Fukutomi T, Mukai K and Hirohashi S: Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res. 82:835–840. 1991. View Article : Google Scholar : PubMed/NCBI
27	Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
28	Yerushalmi R, Woods R, Ravdin PM, Hayes MM and Gelmon KA: Ki67 in breast cancer: Prognostic and predictive potential. Lancet Oncol. 11:174–183. 2010. View Article : Google Scholar : PubMed/NCBI
29	Criscitiello C, Disalvatore D, De Laurentiis M, Gelao L, Fumagalli L, Locatelli M, Bagnardi V, Rotmensz N, Esposito A, Minchella I, et al: High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer. Breast. 23:69–75. 2014. View Article : Google Scholar : PubMed/NCBI
30	Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, et al: International Ki-67 in Breast Cancer Working Group: Assessment of Ki67 in breast cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 103:1656–1664. 2011. View Article : Google Scholar : PubMed/NCBI
31	Honma N, Horii R, Iwase T, Saji S, Younes M, Ito Y and Akiyama F: Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy. Breast Cancer. 22:71–78. 2015. View Article : Google Scholar : PubMed/NCBI
32	Norberg T, Lennerstrand J, Inganäs M and Bergh J: Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors. Int J Cancer. 79:376–383. 1998. View Article : Google Scholar : PubMed/NCBI
33	Done SJ, Arneson CR, Ozçelik H, Redston M and Andrulis IL: p53 protein accumulation in non-invasive lesions surrounding p53 mutation positive invasive breast cancers. Breast Cancer Res Treat. 65:111–118. 2001. View Article : Google Scholar : PubMed/NCBI
34	Lacroix M, Toillon RA and Leclercq G: p53 and breast cancer, an update. Endocr Relat Cancer. 13:293–325. 2006. View Article : Google Scholar : PubMed/NCBI
35	Geisler S, Lønning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA and Børresen-Dale AL: Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 61:2505–2512. 2001.PubMed/NCBI